title: Management of patients with hormone receptor-positive breast cancer with visceral disease: challenges and treatment options.
abstract: Endocrine therapy is an important treatment option for women with hormone receptor-positive (HR+) advanced breast cancer (ABC), yet many tumors are either intrinsically resistant or develop resistance to these therapies. Treatment of patients with ABC presenting with visceral metastases, which is associated with a poor prognosis, is also problematic. There is an unmet need for effective treatments for this patient population. Although chemotherapy is commonly perceived to be more effective than endocrine therapy in managing visceral metastases, patients who are not in visceral crisis might benefit from endocrine therapy, avoiding chemotherapy-associated toxicities that might affect quality of life. To improve outcomes, several targeted therapies are being investigated in combination with endocrine therapy for patients with endocrine-resistant, HR+ ABC. Although available data have considered patients with HR+ ABC as a whole, there are promising data from a prespecified analysis of a Phase III study of everolimus (Afinitor(®)), a mammalian target of rapamycin (mTOR) inhibitor, in combination with exemestane (Aromasin(®)) in patients with visceral disease progressing after nonsteroidal aromatase inhibitor therapy. In this review, challenges and treatment options for management of HR+ ABC with visceral disease, including consideration of therapeutic approaches undergoing clinical investigation, will be assessed.
authors: Horizon Oncology Center, Lafayette, IN, USA.
authors: Wael A
authors: WA
authors: Harb
keywords: endocrine resistance; endocrine therapy; targeted therapy
references: Endocr Rev. 2013 Feb;34(1):1-32
references: 22947396
references: Breast Cancer Res Treat. 2011 Feb;125(3):741-9
references: 20821047
references: Breast Cancer (Dove Med Press). 2014 Apr 17;6:43-57
references: 24833916
references: CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
references: 21296855
references: J Natl Compr Canc Netw. 2004 May;2(3):224-48
references: 19795607
references: J Clin Oncol. 2012 Aug 1;30(22):2718-24
references: 22565002
references: Ann Oncol. 2009 Jul;20(7):1157-62
references: 19221149
references: Expert Rev Anticancer Ther. 2013 Feb;13(2):143-7
references: 23406555
references: Br J Cancer. 1989 Jan;59(1):119-25
references: 2757918
references: Clin Cancer Res. 2010 Mar 15;16(6):1904-14
references: 20215537
references: Adv Ther. 2011 Sep;28 Suppl 6:50-65
references: 21922395
references: Breast Cancer Res Treat. 1999 Jul;56(1):67-78
references: 10517344
references: Clin Cancer Res. 2005 Jul 15;11(14):5319-28
references: 16033851
references: J Clin Oncol. 2013 Jan 10;31(2):195-202
references: 23233719
references: Breast Cancer Res Treat. 2013 Apr;138(3):961-5
references: 23542955
references: Nat Rev Cancer. 2009 Sep;9(9):631-43
references: 19701242
references: Clin Cancer Res. 2004 Dec 1;10(23):8059-67
references: 15585641
references: Cochrane Database Syst Rev. 2003;(2):CD002747
references: 12804433
references: J Cancer Res Clin Oncol. 2013 Apr;139(4):645-52
references: 23283528
references: Clin Breast Cancer. 2010 Feb;10(1):64-73
references: 20133261
references: Curr Oncol Rep. 2013 Feb;15(1):14-23
references: 23054937
references: JAMA. 2013 Feb 27;309(8):800-5
references: 23443443
references: Cancer. 2013 May 15;119(10):1908-15
references: 23504821
references: J Intern Med. 2013 Aug;274(2):144-52
references: 23844917
references: J Clin Oncol. 2008 Apr 1;26(10):1664-70
references: 18316794
references: Am Soc Clin Oncol Educ Book. 2013;:
references: 23714448
references: Am J Epidemiol. 2009 May 15;169(10):1251-9
references: 19318616
references: Breast Cancer (Auckl). 2013;7:7-22
references: 23492649
references: J Clin Oncol. 2005 Mar 10;23(8):1616-22
references: 15755967
references: Eur J Cancer. 2013 Aug;49(12):2621-32
references: 23735704
references: Ann Oncol. 2005 May;16(5):716-25
references: 15817593
references: Anticancer Drugs. 2005 Sep;16(8):797-803
references: 16096426
references: Breast Cancer Res Treat. 2009 Sep;117(1):69-75
references: 19030986
references: Clin Cancer Res. 2011 Mar 1;17(5):1147-59
references: 21220480
references: J Clin Oncol. 2009 Nov 20;27(33):5529-37
references: 19786670
references: Adv Ther. 2013 Oct;30(10):870-84
references: 24158787
references: J Clin Invest. 2011 Oct;121(10):3797-803
references: 21965336
references: Cancer Treat Rev. 2013 Aug;39(5):457-65
references: 22840697
references: Breast Cancer Res Treat. 2011 Apr;126(3):653-61
references: 21347647
references: Curr Oncol. 2013 Feb;20(1):48-61
references: 23443928
references: Breast Cancer Res Treat. 2012 Jul;134(1):267-76
references: 22453754
references: Indian J Med Paediatr Oncol. 2010 Oct;31(4):132-6
references: 21584218
references: Breast. 2006 Oct;15(5):584-94
references: 16504510
references: J Clin Oncol. 2001 May 15;19(10):2596-606
references: 11352951
references: Int J Mol Sci. 2012 Dec 20;14(1):108-45
references: 23344024
references: Curr Med Res Opin. 2013 Nov;29(11):1463-73
references: 23962028
references: Eur J Cancer. 2003 Jun;39(9):1228-33
references: 12763210
references: Cochrane Database Syst Rev. 2009 Oct 07;(4):CD003370
references: 19821307
references: Am J Med Sci. 2010 Oct;340(4):282-90
references: 20881757
references: Clin Breast Cancer. 2009 Feb;9(1):39-44
references: 19299239
references: Clin J Oncol Nurs. 2012 Apr;16(2):E33-43
references: 22459535
references: J Clin Oncol. 2010 Oct 20;28(30):4594-600
references: 20855825
references: Breast Cancer Res Treat. 1983;3(4):365-71
references: 6365209
references: J Clin Oncol. 2013 Jun 10;31(17):2128-35
references: 23650416
references: Int J Cancer. 2013 Oct 1;133(7):1589-602
references: 23553037
references: J Clin Oncol. 2012 Jun 1;30(16):1919-25
references: 22370325
references: N Engl J Med. 2012 Feb 9;366(6):520-9
references: 22149876
references: Curr Cancer Drug Targets. 2010 Aug;10(5):519-28
references: 20384578
references: Breast. 2013 Aug;22(4):405-10
references: 23499266
references: Anticancer Agents Med Chem. 2013 Mar;13(3):464-75
references: 22931419
references: Cancer Treat Rev. 2008 Nov;34(7):640-55
references: 18514425
references: J Clin Oncol. 2009 Nov 20;27(33):5538-46
references: 19786658
references: Breast Cancer Res Treat. 2000 Feb;59(3):271-8
references: 10832597
references: Clin Cancer Res. 2006 Aug 15;12(16):4790-3
references: 16914563
references: Breast Cancer Res Treat. 2003 Dec;82(3):215-22
references: 14703069